Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO — 103), a Potentially Differentiated Nectin — 4/TROP2 Bispecific Antibody — Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026
For best results when printing this announcement, please click on link below: Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 Bispecific Antibody-Drug Conjugate, by Partner VelaVigo at ESMO Asia Congress 2026 - Potential first-in-class d